The latest induced, embryonic, and other pluripotent stem cell news.
Cellular Intelligence will use its AI platform to speed the clinical development and scalable manufacturing of a Phase 1/2 stem cell-derived Parkinson’s therapy acquired from Novo Nordisk, which also took an equity...
Trailhead Biosystems has launched a functionally validated, highly pure iPSC-derived endothelial cell product designed to give researchers a scalable, reproducible human vascular model for angiogenesis, inflammation, drug screening and toxicity studies.
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed an automated manufacturing platform to bring that down, it's currently being used by many companies, including Aspen Neuroscience...
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
South Korea’s KDCA has begun distributing the nation’s first clinical-grade induced pluripotent stem cell lines, a move expected to cut costs and speed development of artificial blood and other cell-based therapies.
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s...
A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
